Shot in arm for Lupin revenue as US approves respiratory drug
Lupin Ltd investors have heaved a sigh of relief. It’s crucial respiratory drug gSpiriva HandiHaler (Tiotropium bromide inhalation powder) received a final approval from the US Food and Drug Administration (USFDA) on Wednesday. Note this nod has come earlier than management’s expectations of July-August this year.
Denial of responsibility! greenleaselibrary.org is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – at email@example.com The content will be deleted within 24 hours.